| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Chemistry, Vol 39, 614-618, Copyright © 1993 by American Association for Clinical Chemistry
A Lipton, L Demers, Y Daniloff, E Curley, C Hamilton, H Harvey, L Witters, J Seaman, R Van der Giessen and S Seyedin
M.S. Hershey Medical Center, Hershey, PA 17033.
Pyridinoline (PYD) and deoxypyridinoline (DPD), two collagen-based cross-links found in bone, were measured by high-performance liquid chromatography in urine samples from 65 control subjects and 97 patients with either untreated or progressive cancer. Patients with cancer had significantly (P < 0.001) higher urine concentrations of PYD and DPD than did control subjects. Both cross-links were increased in cancer patients with and without clinically detectable bone metastases, although patients with bone and liver involvement had higher mean concentrations. The mean concentrations of both cross-links were also significantly higher in the urine samples of inpatients than in an outpatient ambulatory population. These findings suggest that the measurement of PYD and DPD in urine may be useful in assessing bone metastases and bone resorption in cancer patients.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  Y.-C. Chung, C.-H. Ku, T.-Y. Chao, J.-C. Yu, M. M. Chen, and S.-H. Lee Tartrate-resistant Acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 424 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Ali, L. M. Demers, K. Leitzel, H. A. Harvey, D. Clemens, N. Mallinak, L. Engle, V. Chinchilli, L. Costa, C. Brady, et al. Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis Ann. Onc., March 1, 2004; 15(3): 455 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Fohr, C. R. Dunstan, and M. J. Seibel Markers of Bone Remodeling in Metastatic Bone Disease J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5059 - 5075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Buchowski, F. A. de la Fuente, P. J. Flakoll, K. Y. Chen, and E. A. Turner Increased bone turnover is associated with protein and energy metabolism in adolescents with sickle cell anemia Am J Physiol Endocrinol Metab, March 1, 2001; 280(3): E518 - E527. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Demers Biochemical Markers in the Management of Patients with Metastatic Bone Disease Clin. Chem., August 1, 1999; 45(8): 1131 - 1132. [Full Text] [PDF]
|
|
|
|
|
|
A. Berruti, L. Dogliotti, G. Gorzegno, M. Torta, M. Tampellini, M. Tucci, S. Cerutti, M. Mosca Frezet, M. Stivanello, G. Sacchetto, et al. Differential Patterns of Bone Turnover in Relation to Bone Pain and Disease Extent in Bone in Cancer Patients with Skeletal Metastases Clin. Chem., August 1, 1999; 45(8): 1240 - 1247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Van den Berghe, P. Wouters, F. Weekers, S. Mohan, R. C. Baxter, J. D. Veldhuis, C. Y. Bowers, and R. Bouillon Reactivation of Pituitary Hormone Release and Metabolic Improvement by Infusion of Growth Hormone-Releasing Peptide and Thyrotropin-Releasing Hormone in Patients with Protracted Critical Illness J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1311 - 1323. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
